FDA Approves Sarilumab for Adults with Glucocorticoid-Resistant Polymyalgia Rheumatica

On Feb. 28, 2023, the U.S. Food & Drug Administration (FDA) approved sarilumab (Kevzara) for the treatment of adults with polymyalgia rheumatica (PMR) for whom glucocorticoids have proved inadequate or who cannot tolerate a glucocorticoid taper.1,2 Sarilumab is an interleukin (IL) 6 receptor antagonist. In May 2017, the FDA initially approved the agent for the...
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Biologics/DMARDs Conditions Drug Updates Other Rheumatic Conditions Research Rheum glucocorticoid resistant IL-6 IL-6 inhibitors PMR FocusRheum Polymyalgia Rheumatica Research Review sarilumab Source Type: research